Clinical Toxicology最新文献

筛选
英文 中文
Correction.
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-22 DOI: 10.1080/15563650.2024.2430917
{"title":"Correction.","authors":"","doi":"10.1080/15563650.2024.2430917","DOIUrl":"https://doi.org/10.1080/15563650.2024.2430917","url":null,"abstract":"","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"1"},"PeriodicalIF":3.0,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ethanol for the management of alcohol withdrawal syndrome: a systematic review. 乙醇治疗酒精戒断综合征:系统综述。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-19 DOI: 10.1080/15563650.2024.2422964
Darren Quelch, Nyle Davies, Claire McFauld, Arlene Copland, Carol Appleyard, Gareth Roderique-Davies, Sally Bradberry, Bev John
{"title":"Ethanol for the management of alcohol withdrawal syndrome: a systematic review.","authors":"Darren Quelch, Nyle Davies, Claire McFauld, Arlene Copland, Carol Appleyard, Gareth Roderique-Davies, Sally Bradberry, Bev John","doi":"10.1080/15563650.2024.2422964","DOIUrl":"10.1080/15563650.2024.2422964","url":null,"abstract":"<p><strong>Introduction: </strong>Alcohol withdrawal is typically managed using benzodiazepines. However, modulation of both γ-aminobutyric acid-A and N-methyl-d-aspartate-receptors through ethanol provision may provide an alternative management strategy. This systematic review critically analyses the evidence surrounding the use of oral or intravenous ethanol for the management of alcohol withdrawal syndrome.</p><p><strong>Methods: </strong>Systematic searches of ProQuest - American Psychological Association, PsycInfo, MEDLINE and PubMed Central, Web of Science and Embase were performed (Prospero registration number: CRD42023425224). Search criteria were: Population = Patients receiving pharmacological interventions to treat or prevent alcohol withdrawal in a healthcare setting. Intervention = intravenous or enteral ethanol. Comparator = standard care, benzodiazepines, carbamazepine, adjunct medications including sedatives, or no comparator. Outcomes = complication rates, symptom scores, length of stay in healthcare settings. Exclusions were: preclinical studies, participants less than 18 years old, non-peer reviewed literature, poor study design or poor data quality. Study quality was assessed using an adapted National Institute for Health and Care Research quality tool. A narrative data synthesis approach was adopted.</p><p><strong>Results: </strong>Eight thousand two hundred and four studies were retrieved. Ten were included in the final analysis. Overall study quality was poor. Seven studies reported treatment outcomes that were comparable to a control arm or in which ethanol conferred no detrimental effect. Three studies reported positive outcomes, and one study reported worse outcomes following ethanol administration.</p><p><strong>Discussion: </strong>The review identified heterogeneity in study design and limited reporting surrounding patient demographics, patient alcohol use history and the practicalities of ethanol administration. As such, implementation of ethanol prescribing for the management of alcohol withdrawal is currently limited due to the quality and translatability of existing data surrounding its use.</p><p><strong>Conclusions: </strong>Further studies are required with more transparent and complete outcome reporting and practical implementation recommendations in order to facilitate the translation of ethanol prescribing for the management of alcohol withdrawal syndrome.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"1-13"},"PeriodicalIF":3.0,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 10-year retrospective review of exposures to volatile nitrites reported to the Victorian Poisons Information Centre. 对维多利亚州毒药信息中心报告的接触挥发性亚硝酸盐的情况进行了为期 10 年的回顾性审查。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-11 DOI: 10.1080/15563650.2024.2423832
James White, Rohan A Elliott
{"title":"A 10-year retrospective review of exposures to volatile nitrites reported to the Victorian Poisons Information Centre.","authors":"James White, Rohan A Elliott","doi":"10.1080/15563650.2024.2423832","DOIUrl":"https://doi.org/10.1080/15563650.2024.2423832","url":null,"abstract":"<p><strong>Introduction: </strong>Volatile nitrites, such as amyl nitrite, are used recreationally to enhance sexual experience and provide a feeling of euphoria. They are associated with severe adverse reactions including methaemoglobinaemia and maculopathy. The aim of this study was to explore the epidemiology and clinical effects of volatile nitrite exposures reported to the Victorian Poisons Information Centre in Australia over a 10-year period.</p><p><strong>Methods: </strong>This was a retrospective, observational study of poison centre call records. Data were extracted for all exposures to volatile nitrites reported from 2013 to 2022.</p><p><strong>Results: </strong>There were 132 calls about volatile nitrites, representing 122 exposures, with a more than five-fold increase in the annual number of exposures (from five in 2013 to 26 in 2022). Ingestion (49.2%) and inhalation (27.9%) were the most common routes of exposure. Seventy-six (62.3%) patients reported one or more symptoms related to volatile nitrite exposure. The most common symptoms were light-headedness/dizziness (20.5%), oro-mucosal irritation (15.6%), ocular irritation (14.8%), nasal irritation (12.3%), and nausea/vomiting (9.8%). Less common, but potentially serious, adverse effects included methaemoglobinaemia (4.1%), hypoxia (1.6%) and hypotension (0.8%). Symptom severity was usually classified as minor (70/76, 92.1%) at the time of the poisons centre call. Fifty-four (44.3%) patients were either in the hospital when the poisons centre was contacted or were referred to the hospital by the poisons centre.</p><p><strong>Discussion: </strong>The increase in reported volatile nitrite exposures observed in this study aligns with epidemiological data showing an increase in volatile nitrite usage in Australia. The findings about the nature of exposures and symptoms experienced can be used to inform harm reduction and education efforts for community members and health professionals.</p><p><strong>Conclusions: </strong>Exposures to volatile nitrites reported to an Australian poisons centre increased between 2013 and 2022. More than 40% of exposures resulted in a hospital presentation. Methaemoglobinaemia was reported in 4.1% of cases.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"1-5"},"PeriodicalIF":3.0,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142615697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Response to West et al. "Identifying and quantifying exposures involving counterfeit opioid analgesic products". 对 West 等人 "识别和量化涉及假冒阿片类镇痛药产品的暴露 "的回应。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-06 DOI: 10.1080/15563650.2024.2421862
Yun-Ling Liu, Lien-Chung Wei
{"title":"Response to West et al. \"Identifying and quantifying exposures involving counterfeit opioid analgesic products\".","authors":"Yun-Ling Liu, Lien-Chung Wei","doi":"10.1080/15563650.2024.2421862","DOIUrl":"10.1080/15563650.2024.2421862","url":null,"abstract":"","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"1-4"},"PeriodicalIF":3.0,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of hypofibrinogenemia following rattlesnake envenomation treated with crotalidae immune F(ab')2 (equine) antivenom. 响尾蛇中毒后使用巴豆科免疫 F(ab')2(马)抗蛇毒血清治疗的低纤维蛋白原血症的特征。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-09-25 DOI: 10.1080/15563650.2024.2406427
Thom S Maciulewicz, David R Axon, Farshad Mazda Shirazi
{"title":"Characterization of hypofibrinogenemia following rattlesnake envenomation treated with crotalidae immune F(ab')<sub>2</sub> (equine) antivenom.","authors":"Thom S Maciulewicz, David R Axon, Farshad Mazda Shirazi","doi":"10.1080/15563650.2024.2406427","DOIUrl":"10.1080/15563650.2024.2406427","url":null,"abstract":"<p><strong>Introduction: </strong>Hemotoxicity is common following rattlesnake envenomation. Published experiences with equine-derived crotalidae immune F(ab')<sub>2</sub> antivenom have characterized hemotoxicity as delayed, recurrent, or persistent. This study investigated recovery of hypofibrinogenemia following rattlesnake envenomation treated with equine-derived crotalidae immune F(ab')<sub>2</sub> antivenom.</p><p><strong>Methods: </strong>This is a retrospective analysis of human rattlesnake envenomations reported to the Arizona Poison and Drug Information Center over four years. We included rattlesnake-envenomated patients who developed hypofibrinogenemia (<1,500 mg/L) and were treated with equine-derived crotalidae immune F(ab')<sub>2</sub> antivenom. The primary outcomes were recovery period (h) and recovery rate (mg/L/h) of hypofibrinogenemia following equine-derived crotalidae immune F(ab')<sub>2</sub> antivenom administration. Collected data included demographics, laboratory values, and antivenom administered. Statistics used were percentages, medians, and Kruskall-Wallis test.</p><p><strong>Results: </strong>There were 527 rattlesnake envenomations treated with antivenom, of which 80 met the inclusion criteria. Patients receiving treatment with F(ab')<sub>2</sub> antivenom and had a median fibrinogen concentration recovery rate of 62.3 mg/L/h (IQR: 42.0-74.3 mg/L/h) and median recovery period of 19.2 h (IQR: 13.8-26.2 h). There were statistically significant differences between categories for time to antivenom for the median recovery period (<i>P</i> = 0.0154).</p><p><strong>Discussion: </strong>Hypofibrinogenemia is a common laboratory finding following rattlesnake envenomation in Arizona. This study investigated rattlesnake envenomated patients treated with F(ab')<sub>2</sub> antivenom and monitored fibrinogen concentrations as a surrogate marker of venom toxicity. Additionally, time to administration of F(ab')<sub>2</sub> antivenom was a statistical significant marker of the recovery period from hypofibrinogenemia. Limitations of this study included the geographic coverage of the poison center and exclusion of patients with insufficient laboratory monitoring or those who received another antivenom.</p><p><strong>Conclusions: </strong>Following rattlesnake envenomation in Arizona, recovery from hypofibrinogenemia was able characterized in a rate (mg/L/h) and period (h) with the quantity and time to administration of antivenom. More studies are needed to assess this finding with other antivenoms and its clinical significance.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"749-753"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An outbreak of Galerina sulciceps-like (Galerina cf. sulciceps) mushroom poisoning. 蘑菇中毒(Galerina cf. sulciceps)爆发。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-09-20 DOI: 10.1080/15563650.2024.2402501
Mengxia Cao, Shan Luo, Ting Kang, Santao Ou
{"title":"An outbreak of <i>Galerina sulciceps</i>-like (Galerina cf. sulciceps) mushroom poisoning.","authors":"Mengxia Cao, Shan Luo, Ting Kang, Santao Ou","doi":"10.1080/15563650.2024.2402501","DOIUrl":"10.1080/15563650.2024.2402501","url":null,"abstract":"<p><strong>Objective: </strong>Amatoxin-containing mushroom poisoning is a significant threat to public health worldwide. We report a mass poisoning of <i>Galerina sulciceps</i>-like mushrooms (Galerina cf. sulciceps) in Luzhou, Sichuan Province, China, aiming to offer insights for future prevention and treatment strategies.</p><p><strong>Methods: </strong>We performed a retrospective survey of mass mushroom poisoning patients admitted to our hospital. The demographic data, clinical presentations, laboratory findings, therapeutic measures and prognostic information were collected and analyzed. We used the 2020 Chinese consensus on the clinical diagnosis and treatment of amatoxin-containing mushroom poisoning to assess the severity of poisoning. Mushrooms were examined through morphological analysis, molecular biology identification, and toxin detection.</p><p><strong>Results: </strong>Our patient cohort consisted of nine males and six females, with mean (±SD) age of 34.9 ± 13.0 years. Gastrointestinal symptoms were the first to manifest, with mean (±SD) latency period of 13.4 ± 3.9 h. The majority of patients (86.7%) experienced nausea, vomiting, and diarrhea. Liver dysfunction was noted in 66.7% of patients, and thrombocytopenia was present in 26.7% of patients. In terms of the severity of poisoning, there were 10 mild cases and five severe cases. The mushrooms were provisionally labeled as <i>Galerina cf. sulciceps</i>, containing the toxins α-amanitin, β-amanitin, and γ-amanitin. All patients eventually recovered.</p><p><strong>Discussion: </strong>We report what appears to be a new type of mushroom that is morphologically and phylogenetically similar to the known <i>Galerina sulciceps</i>, but further study is required to determine if it represents a distinct species.</p><p><strong>Conclusion: </strong>This poisoning event was caused by unintentional ingestion of <i>Galerina cf. sulciceps</i>, an amatoxin-containing mushroom. Early symptoms are primarily gastrointestinal, with acute liver damage and coagulopathy being the main toxic effects. Thrombocytopenia is also prominent, particularly in severe cases. Accurate assessment and prompt, individualized, and intensive treatment are crucial for managing patients with acute <i>Galerina cf. sulciceps</i> poisoning effectively.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"707-713"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrections. 更正。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1080/15563650.2024.2415238
{"title":"Corrections.","authors":"","doi":"10.1080/15563650.2024.2415238","DOIUrl":"10.1080/15563650.2024.2415238","url":null,"abstract":"","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"786"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The trajectory of serum salicylate concentrations after ingestion of medicinal oil containing methyl salicylate. 摄入含水杨酸甲酯的药油后血清中水杨酸盐浓度的变化轨迹。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-10-10 DOI: 10.1080/15563650.2024.2409826
Rex Pui Kin Lam, Chi Keung Chan, Man Li Tse, Anthony T Y Chow, Esther W Y Chan, Timothy Hudson Rainer
{"title":"The trajectory of serum salicylate concentrations after ingestion of medicinal oil containing methyl salicylate.","authors":"Rex Pui Kin Lam, Chi Keung Chan, Man Li Tse, Anthony T Y Chow, Esther W Y Chan, Timothy Hudson Rainer","doi":"10.1080/15563650.2024.2409826","DOIUrl":"10.1080/15563650.2024.2409826","url":null,"abstract":"<p><strong>Introduction: </strong>The toxicokinetics of methyl salicylate after unintentional or intentional ingestion of medicinal oil containing methyl salicylate has not been well studied. We aimed to characterize the trajectory of serum salicylate concentrations and to evaluate factors associated with the peak serum salicylate concentration and the time from ingestion to peak concentration.</p><p><strong>Methods: </strong>This was a retrospective cohort study of consecutive patients reported to the Hong Kong Poison Control Centre for laboratory-confirmed methyl salicylate poisoning by all local public emergency departments between 1 July 2008 and 30 June 2023. We analyzed cases with at least three serum salicylate concentrations. Multivariable generalized linear regression was used to identify factors significantly associated with the peak serum concentration and the time from ingestion to peak concentration.</p><p><strong>Results: </strong>We included 41 patients (median age 81.0 years; 32 women and nine men). The median time from ingestion to the first peak serum salicylate concentration was 5.6 h (IQR: 3.2-10.8 h). Multiple regression showed that gastric aspiration (adjusted regression coefficient [β] - 2.50; 95% CI: -3.93 to -1.08; <i>P</i> = 0.001) and single-dose activated charcoal (adjusted β - 1.22; 95% CI: -2.02 to -0.42; <i>P</i> = 0.003) were significantly associated with a lower peak concentration, after adjusting for patient age, sex, exposure due to intentional self-harm, reported ingested dose, time from ingestion to emergency department presentation, vomiting, concurrent use of aspirin (acetylsalicylic acid) and other medications that affect gastric emptying or gastric acid secretion, blood pH, serum albumin concentration, and creatinine clearance.</p><p><strong>Discussion: </strong>The serum salicylate concentration did not peak as quickly as generally believed, highlighting the importance of continued monitoring. Gastric aspiration and single-dose activated charcoal may help reduce gastrointestinal absorption, but their impact on clinical outcomes remains unclear.</p><p><strong>Conclusions: </strong>Given the median time of 5.6 h (IQR: 3.2-10.8 h) from ingestion to the peak salicylate concentration, gastric aspiration and single-dose activated charcoal can be considered in patients up to a few hours after medicinal oil ingestion when the airway is protected.</p>","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"733-742"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An unexpected place for a fentanyl patch. 芬太尼贴片的意外位置
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-09-28 DOI: 10.1080/15563650.2024.2407056
Marianne E C Leenders, Corine C Visser, Dylan W de Lange
{"title":"An unexpected place for a fentanyl patch.","authors":"Marianne E C Leenders, Corine C Visser, Dylan W de Lange","doi":"10.1080/15563650.2024.2407056","DOIUrl":"10.1080/15563650.2024.2407056","url":null,"abstract":"","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"782-783"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction. 更正。
IF 3 3区 医学
Clinical Toxicology Pub Date : 2024-11-01 Epub Date: 2024-10-08 DOI: 10.1080/15563650.2024.2412421
{"title":"Correction.","authors":"","doi":"10.1080/15563650.2024.2412421","DOIUrl":"10.1080/15563650.2024.2412421","url":null,"abstract":"","PeriodicalId":10430,"journal":{"name":"Clinical Toxicology","volume":" ","pages":"785"},"PeriodicalIF":3.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信